Immunizing against Alzheimer's

Immunization with amyloid-beta peptide reduces the learning deficits seen in mouse models of Alzheimer's disease.

By | December 22, 2000

Abnormal processing and deposition of amyloid-β peptide (Aβ) in extracellular plaques are thought to be central to the pathogenesis of Alzheimer's disease. Immunization with Aβ reduces the amount of brain amyloid, and now in the 21/28 December Nature, Janus et al. (Nature 2000, 408:979-982) and Morgan et al. (Nature 2000, 408:982-985) report that similar immunization protocols also reduce the learning deficit seen in mouse models of Alzheimer's disease.

Janus et al. immunize at 6, 8, 12, 16 and 20 weeks with Aβ in β-pleated sheet conformation, and test using a Morris water maze at 11, 15, 19 and 23 weeks. The immunized mice perform significantly better than non-immunized littermates at 11 and 23 weeks, when two discrete increases in amyloid burden are detected in non-immunized mice. Immunization reduces the amount of dense-cored Aβ plaques by approximately 50%, suggesting that the elicited antibodies may inhibit assembly of Aβ fibrils rather than clear all Aβ.

Morgan et al. immunize monthly before assaying at 15.5 months using a radial-arm water maze that tests working memory. (Chen et al., reporting in the same issue of Nature, find that only the performance of tasks that require this sort of working or episodic-like memory are correlated with the age-related increase in plaque burden (Nature 2000, 408:975-979).) At 15.5 months the immunized mice are better than non-immunized mice on the fourth trial, and as good as wild-type mice by the fifth trial. In contrast the mice in the Janus et al. study never improved to reach the performance levels of wild-type mice. Morgan et al., the group not affiliated with a pharmaceutical company, "strongly recommend testing" of Aβ immunization for both treatment and prevention of Alzheimer's disease.

Further links to Aβ come in the 22 December Science. Ertekin-Taner et al. use plasma Aβ42 levels as a surrogate for late-onset Alzheimer's disease (LOAD), and come up with a locus on chromosome 10 linked to the disease (Science 2000, 290:2303-2304). Myers et al. confirm this observation using an analysis of affected sibling pairs, and find a significance level that suggests the new locus is as important as the E4 allele of apolipoprotein E, the only known genetic risk factor for LOAD (Science 2000, 290:2304-2305). The new locus is near, but apparently distinct from, the locus identified by Bertram et al. (Science 2000, 290:2302-2303). The latter locus is very near or identical to the gene for insulin-degrading enzyme, which may help degrade and clear Aβ.

Popular Now

  1. Broad Wins CRISPR Patent Interference Case
    Daily News Broad Wins CRISPR Patent Interference Case

    The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.

  2. Henrietta Lacks’s Family Seeks Compensation
  3. Cannibalism: Not That Weird
    Reading Frames Cannibalism: Not That Weird

    Eating members of your own species might turn the stomach of the average human, but some animal species make a habit of dining on their own.

  4. Can Plants Learn to Associate Stimuli with Reward?
Business Birmingham